SURMOUNT-2

CompletedPhase 3Results posted

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

938

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27•HbA1c 7-10%

Primary endpoints

•Body weight, % change•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04657003

Org study ID17245

Secondary IDI8F-MC-GPHLEli Lilly and Company

Timeline

Milestones

Study first posted2020-12-07actual

Study start2021-03-29actual

Primary completion2023-03-16actual

Study completion2023-04-10actual

Last update posted2024-04-08actual

Results first posted2024-04-08actual

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have Type 2 Diabetes (T2DM) with HbA1c ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)

•Have a BMI of ≥27 kg/m²

•Are overweight or have obesity

•Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

•Are at least 18 years of age and age of majority per local laws and regulations

Exclusion criteria

•Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM

•Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values >270 mg/dL(on 2 nonconsecutive days) prior to Visit 3

•Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment

•Have self-reported change in body weight >5kg within 3 months prior to screening

•Have had a history of chronic or acute pancreatitis

•Change in body weight greater than 5 kg within 3 months prior to starting study

•Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity

•Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

•History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years

•Any lifetime history of a suicide attempt

Endpoints (52)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Weight & body composition

Glycemic / diabetes

Patient-reported / QoL

Safety / tolerability / PK

Weight & body composition

16 endpoints

Primary/registry result

Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 72

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	-3.3	—
10 mg Tirzepatide	-13.4	—
15 mg Tirzepatide	-15.7	—

LSMean Mean Difference (Net)-10.195% CI-11.5 – -8.8p<0.001Mixed Models Analysis

LSMean Mean Difference (Net)-12.495% CI-13.7 – -11.0p<0.001Mixed Models Analysis

Primary/registry result

Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline

Time frame:Week 72

≥5% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	30.55	—
10 mg Tirzepatide	81.55	—
15 mg Tirzepatide	86.41	—

Odds Ratio (OR)10.7595% CI7.30 – 15.84p<0.001Regression, Logistic

Odds Ratio (OR)15.2895% CI10.08 – 23.14p<0.001Regression, Logistic

Primary/protocol endpoint

Percent Change From Baseline in Body Weight

Time frame:Baseline, Week 72

Body weight, % change

percent change from baseline, improvement

Primary/protocol endpoint

Percentage of Participants Who Achieve ≥5% Body Weight Reduction From Baseline

Time frame:Week 72

≥5% weight-loss responders

threshold achievement, improvement

Secondary/registry result

Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline

Time frame:Week 72

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	8.68	—
10 mg Tirzepatide	63.43	—
15 mg Tirzepatide	69.58	—

Odds Ratio (OR)20.9495% CI13.06 – 33.58p<0.001Regression, Logistic

Odds Ratio (OR)27.5095% CI17.04 – 44.39p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline

Time frame:Week 72

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	2.57	—
10 mg Tirzepatide	41.42	—
15 mg Tirzepatide	51.78	—

Odds Ratio (OR)28.3895% CI13.81 – 58.31p<0.001Regression, Logistic

Odds Ratio (OR)43.6095% CI21.20 – 89.67p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline

Time frame:Week 72

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	0.96	—
10 mg Tirzepatide	22.98	—
15 mg Tirzepatide	33.98	—

Odds Ratio (OR)28.5495% CI9.73 – 83.73p<0.001Regression, Logistic

Odds Ratio (OR)49.6895% CI17.03 – 144.94p<0.001Regression, Logistic

Secondary/registry result

Change From Baseline in Absolute Body Weight

Time frame:Baseline, Week 72

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms (kg)	95% CI
Placebo	-3.2	—
10 mg Tirzepatide	-13.5	—
15 mg Tirzepatide	-15.6	—

LSMean Mean Difference (Net)-10.395% CI-11.7 – -8.8p<0.001Mixed Models Analysis

LSMean Mean Difference (Net)-12.495% CI-13.8 – -11.0p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 72

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilograms per meter squared (kg/m^2)	95% CI
Placebo	-1.2	—
10 mg Tirzepatide	-4.9	—
15 mg Tirzepatide	-5.7	—

LSMean Mean Difference (Net)-3.795% CI-4.2 – -3.2p<0.001Mixed Models Analysis

LSMean Mean Difference (Net)-4.595% CI-5.0 – -4.0p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Waist Circumference

Time frame:Baseline, Week 72

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), centimeters (cm)	95% CI
Placebo	-3.4	—
10 mg Tirzepatide	-11.2	—
15 mg Tirzepatide	-13.8	—

LSMean Mean Difference (Net)-7.895% CI-9.2 – -6.4p<0.001Mixed Models Analysis

LSMean Mean Difference (Net)-10.495% CI-11.8 – -8.9p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥10% Body Weight Reduction From Baseline

Time frame:Week 72

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥15% Body Weight Reduction From Baseline

Time frame:Week 72

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥20% Body Weight Reduction From Baseline

Time frame:Week 72

≥20% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change From Baseline in Absolute Body Weight

Time frame:Baseline, Week 72

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 72

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Waist Circumference

Time frame:Baseline, Week 72

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

12 endpoints

Secondary/registry result

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 72

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
Placebo	-0.16	—
10 mg Tirzepatide	-2.14	—
15 mg Tirzepatide	-2.22	—

LSMean Mean Difference (Net)-1.9795% CI-2.15 – -1.80p<0.001Mixed Models Analysis

LSMean Mean Difference (Net)-2.0695% CI-2.24 – -1.88p<0.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants Who Achieve HbA1c <7%

Time frame:Week 72

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	29.31	—
10 mg Tirzepatide	90.03	—
15 mg Tirzepatide	90.67	—

Odds Ratio (OR)28.0195% CI17.21 – 45.59p<0.001Regression, Logistic

Odds Ratio (OR)34.1995% CI20.27 – 57.67p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve HbA1c ≤6.5%

Time frame:Week 72

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	15.52	—
10 mg Tirzepatide	84.05	—
15 mg Tirzepatide	86.67	—

Odds Ratio (OR)42.1195% CI25.61 – 69.26p<0.001Regression, Logistic

Odds Ratio (OR)58.6795% CI34.29 – 100.37p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve HbA1c <5.7%

Time frame:Week 72

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	2.76	—
10 mg Tirzepatide	50.17	—
15 mg Tirzepatide	55.33	—

Odds Ratio (OR)42.5595% CI20.46 – 88.50p<0.001Regression, Logistic

Odds Ratio (OR)54.3095% CI26.00 – 113.38p<0.001Regression, Logistic

Secondary/registry result

Change From Baseline in Fasting Glucose

Time frame:Baseline, Week 72

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligrams per deciliter (mg/dL)	95% CI
Placebo	-2.42	—
10 mg Tirzepatide	-49.20	—
15 mg Tirzepatide	-51.67	—

LSMean Mean Difference (Net)-46.7995% CI-52.67 – -40.91p<0.001Mixed Models Analysis

LSMean Mean Difference (Net)-49.2595% CI-55.18 – -43.33p<0.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Fasting Insulin

Time frame:Baseline, Week 72

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Placebo	-14.5	—
10 mg Tirzepatide	-29.6	—
15 mg Tirzepatide	-40.3	—

Estimate Difference-17.695% CI-25.5 – -8.9p<0.001Mixed Models Analysis

Estimate Difference-30.295% CI-37.0 – -22.7p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Change From Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 72

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants Who Achieve HbA1c <7%

Time frame:Week 72

HbA1c <7.0% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants Who Achieve HbA1c ≤6.5%

Time frame:Week 72

HbA1c <6.5% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percentage of Participants Who Achieve HbA1c <5.7%

Time frame:Week 72

HbA1c <5.7% achievement

threshold achievement, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change From Baseline in Fasting Glucose

Time frame:Baseline, Week 72

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Percent Change From Baseline in Fasting Insulin

Time frame:Baseline, Week 72

percent change from baseline, improvement

Cardiometabolic biomarkers

18 endpoints

Secondary/registry result

Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

Total cholesterol, change

percent change from baseline, improvement

LOINC 2093-3

Posted result

Group	Value (mean), percent change	95% CI
Placebo	2.13	—
Pooled 10 mg and 15 mg Tirzepatide	-2.58	—

Estimate Difference-4.6195% CI-7.11 – -2.03p<0.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

LDL-C, change

percent change from baseline, improvement

LOINC 13457-7

Posted result

Group	Value (mean), percent change	95% CI
Placebo	6.29	—
Pooled 10 mg and 15 mg Tirzepatide	2.72	—

Estimate Difference-3.3695% CI-7.36 – 0.81p0.112Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

HDL-C, change

percent change from baseline, improvement

LOINC 2085-9

Posted result

Group	Value (mean), percent change	95% CI
Placebo	1.10	—
Pooled 10 mg and 15 mg Tirzepatide	8.19	—

Estimate Difference7.0295% CI4.40 – 9.71p<0.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

VLDL, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Placebo	-6.0	—
Pooled 10 mg and 15 mg Tirzepatide	-27.9	—

Estimate Difference-23.395% CI-27.5 – -18.9p<0.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Posted result

Group	Value (mean), percent change	95% CI
Placebo	-5.8	—
Pooled 10 mg and 15 mg Tirzepatide	-28.6	—

Estimate Difference-24.295% CI-28.6 – -19.6p<0.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

Non-HDL cholesterol, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Placebo	2.30	—
Pooled Doses of 10 mg and 15 mg Tirzepatide	-6.64	—

Estimate Difference-8.7495% CI-12.04 – -5.32p<0.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Time frame:Baseline, Week 72

Free fatty acids, change

percent change from baseline, improvement

Posted result

Group	Value (mean), percent change	95% CI
Placebo	0.03	—
Pooled 10 mg and 15 mg Tirzepatide	-23.58	—

Estimate Difference-23.6195% CI-28.62 – -18.24p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Time frame:Baseline, Week 72

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (least_squares_mean), millimeters of mercury (mmHg)	95% CI
Placebo	-1.0	—
Pooled 10 mg and 15 mg Tirzepatide	-7.2	—

LSMean Mean Difference (Net)-6.295% CI-8.0 – -4.4p<0.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Time frame:Baseline, Week 72

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Posted result

Group	Value (least_squares_mean), millimeters of mercury (mmHg)	95% CI
Placebo	-0.2	—
Pooled Doses of 10 mg and 15 mg Tirzepatide	-2.6	—

LSMean Mean Difference (Net)-2.495% CI-3.5 – -1.3p<0.001Mixed Models Analysis

Secondary/protocol endpoint

Percent Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

Total cholesterol, change

percent change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

LDL-C, change

percent change from baseline, improvement

LOINC 13457-7

Secondary/protocol endpoint

Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

HDL-C, change

percent change from baseline, improvement

LOINC 2085-9

Secondary/protocol endpoint

Percent Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

VLDL, change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Percent Change From Baseline in Non-High Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

Time frame:Baseline, Week 72

Non-HDL cholesterol, change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change From Baseline in Free Fatty Acids (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Time frame:Baseline, Week 72

Free fatty acids, change

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Time frame:Baseline, Week 72

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Secondary/protocol endpoint

Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of 10 mg and 15 mg Tirzepatide)

Time frame:Baseline, Week 72

Diastolic BP, change

change from baseline, improvement

LOINC 8462-4

Patient-reported / QoL

4 endpoints

Secondary/registry result

Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

Time frame:Baseline, Week 72

SF-36 physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), score on a scale	95% CI
Placebo	1.6	—
10 mg Tirzepatide	3.4	—
15 mg Tirzepatide	3.8	—

LSMean Mean Difference (Net)1.895% CI0.7 – 2.9p0.001ANCOVA

LSMean Mean Difference (Net)2.395% CI1.1 – 3.4p<0.001ANCOVA

Secondary/registry result

Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score

Time frame:Baseline, Week 72

IWQOL-Lite physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), score on a scale	95% CI
Placebo	7.4	—
10 mg Tirzepatide	14.3	—
15 mg Tirzepatide	15.2	—

LSMean Difference (Net)6.995% CI4.1 – 9.7p<0.001ANCOVA

LSMean Difference (Net)7.895% CI5.0 – 10.7p<0.001ANCOVA

Secondary/protocol endpoint

Change From Baseline in Short Form 36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

Time frame:Baseline, Week 72

SF-36 physical

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL Lite-CT) Physical Function Composite Score

Time frame:Baseline, Week 72

IWQOL-Lite physical

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Secondary/registry result

Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide

Time frame:Week 8, 16, 36: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose

AUC₀–∞

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogramshour per milliliter (ngh/mL)	95% CI
10 mg Tirzepatide	153000	—
15 mg Tirzepatide	234000	—

Secondary/protocol endpoint

Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide

Time frame:Week 8, 16, 36: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours postdose

AUC₀–∞

concentration, descriptive

Publications (6)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.
Obesity pillars2026 Mar (month)PMID41640675doi:10.1016/j.obpill.2026.100248via pubmed nct search
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
Obesity (Silver Spring, Md.)2026 Mar (month)PMID41537305doi:10.1002/oby.70122via clinicaltrials gov reference derived + pubmed nct search
Kidney Parameters with Tirzepatide in Obesity with or without Type 2 Diabetes.
Journal of the American Society of Nephrology : JASN2025 Nov 1PMID40512543doi:10.1681/ASN.0000000764via clinicaltrials gov reference derived + pubmed nct search
Tirzepatide Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial.
Diabetes therapy : research, treatment and education of diabetes and related disorders2025 May (month)PMID40120035doi:10.1007/s13300-025-01723-wvia clinicaltrials gov reference derived + pubmed nct search
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet (London, England)2023 Aug 19PMID37385275doi:10.1016/S0140-6736(23)01200-Xvia clinicaltrials gov reference derived + pubmed nct search
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
Obesity (Silver Spring, Md.)2023 Jan (month)PMID36478180doi:10.1002/oby.23612via pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.